Search results
Showing 551 to 600 of 3765 results for treatment
Cardiovascular disease: identifying and supporting people most at risk of dying early (PH15)
This guideline covers the risk of early death from heart disease and other smoking-related illnesses. It aims to reduce the number of people who are disadvantaged dying prematurely by ensuring people have better access to flexible, well-coordinated treatment and support.
Sequencing and further line treatment:- What is the clinical and cost effectiveness of sequencing and further line...
Awaiting development Reference number: GID-TA11403 Expected publication date: TBC
This quality standard covers diagnosing and managing common types of headache in adults and young people (aged 12 and over). It includes tension-type headache, migraine, cluster headache and medication overuse headache. It describes high-quality care in priority areas for improvement.
View quality statements for QS42Show all sections
Sections for QS42
- Quality statements
- Quality statement 1: Classification of headache type
- Quality statement 2: Preventing medication overuse headache
- Quality statement 3: Imaging
- Quality statement 4: Combined treatment for migraine
- Quality statement 5 (placeholder): Raising public and professional awareness
- Update information
- About this quality standard
This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.
This guideline covers preventing, assessing and managing mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It aims to improve assessment and support for mental health conditions, and help people with learning disabilities and their families and carers to be involved in their care.
Hormonal and hormone-modifying treatment option: What is the effectiveness of hormone-modifying agents in the treatment of...
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
View recommendations for MPG1Show all sections
Antisocial behaviour and conduct disorders in children and young people (QS59)
This quality standard covers recognising and managing antisocial behaviour and conduct disorders in children and young people. It describes high-quality care in priority areas for improvement.
View quality statements for QS59Show all sections
Sections for QS59
- Quality statements
- Quality statement 1: Early intervention
- Quality statement 2: Comprehensive assessment
- Quality statement 3: Improving access to services
- Quality statement 4: Parent or carer training
- Quality statement 5: Multimodal interventions
- Quality statement 6: Monitoring adverse effects of pharmacological interventions
- Update information
This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.
This quality standard covers preventing dementia, and assessment, management and health and social care support for people with dementia. It describes high-quality care in priority areas for improvement.
View quality statements for QS184Show all sections
Sections for QS184
- Quality statements
- Quality statement 1: Raising awareness – health promotion interventions
- Quality statement 2: Diagnosis
- Quality statement 3: Advance care planning
- Quality statement 4: Coordinating care
- Quality statement 5: Activities to promote wellbeing
- Quality statement 6: Managing distress
- Quality statement 7: Supporting carers
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)
Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for malignant diseases in people for whom a reduced intensity regimen would be suitable.
In development Reference number: GID-TA11813 Expected publication date: TBC
Babies, children and young people's experience of healthcare (NG204)
This guideline describes good patient experience for babies, children and young people, and makes recommendations on how it can be delivered. It aims to make sure that all babies, children and young people using NHS services have the best possible experience of care. It is recognised that parents and carers play a key role, and where appropriate, we took their views into account when developing the recommendations.
Fever in under 5s: assessment and initial management (NG143)
This guideline covers the assessment and early management of fever with no obvious cause in children aged under 5. It aims to improve clinical assessment and help healthcare professionals diagnose serious illness among young children who present with fever in primary and secondary care.
after successful treatment of anorexia nervosa:- What factors (including comorbidities, personal, social and demographic factors,...
Awaiting development Reference number: GID-TA11137 Expected publication date: TBC
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]
Awaiting development Reference number: GID-TA11881 Expected publication date: TBC
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.
Awaiting development Reference number: GID-TA11438 Expected publication date: TBC
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
View recommendations for MPG2Show all sections
Question Combination treatment for Parkinson's disease dementia:- What is the effectiveness of combination treatment with...
Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
Evidence-based recommendations on carfilzomib (Kyprolis) with dexamethasone and lenalidomide (Revlimid) for previously treated multiple myeloma in adults.
Evidence-based recommendations on naltrexone (Nalorex) for managing opioid dependence in adults.
This quality standard covers managing acute painful episodes of sickle cell disease in hospital. It includes pain relief and care for children, young people and adults, from presentation in hospital until discharge. It describes high-quality care in priority areas for improvement.
View quality statements for QS58Show all sections
Sections for QS58
- Quality statements
- Quality statement 1: Timely assessment and analgesia
- Quality statement 2: Regular assessment of pain relief
- Quality statement 3: Strong opioids and monitoring
- Quality statement 4: Acute complications
- Quality statement 5: Protocols and specialist support
- Quality statement 6: Discharge information
- Update information
This guideline covers the transition between inpatient hospital settings and community or care homes for adults with social care needs. It aims to improve people's experience of admission to, and discharge from, hospital by better coordination of health and social care services.
Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.
In development Reference number: GID-TA11440 Expected publication date: TBC
Ixekizumab for treating moderate to severe plaque psoriasis (TA442)
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)
Evidence-based recommendations on brigatinib (Alunbrig) for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults who have already had crizotinib.
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
glioma: early detection of recurrence after treatment:- Does early detection of recurrence after treatment improve overall...
Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)
Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.
Awaiting development Reference number: GID-TA11869 Expected publication date: TBC
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
View recommendations for TA330Show all sections
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)
This guideline covers diagnosing and managing idiopathic pulmonary fibrosis in people aged 18 and over. It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management.
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)
Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
This quality standard covers diagnosing and managing epilepsies in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS211Show all sections
Sections for QS211
- Quality statements
- Quality statement 1: Referral and assessment after first seizure
- Quality statement 2: Referral to tertiary specialist services
- Quality statement 3: Epilepsy specialist nurse
- Quality statement 4: Epilepsy care plan
- Quality statement 5: Mental health and wellbeing
- Quality statement 6: Neurodevelopment and learning disabilities
- Update information
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)
Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.